Arthritis refers to a collection of diseases that affect the joints, causing pain and stiffness. There are more than one hundred types of arthritis which can be broadly categorised as either inflammatory or non-inflammatory.
Non-inflammatory arthritis includes osteoarthritis, the most common form of arthritis. Osteoarthritis involves degeneration of the articular cartilage that protects the ends of the bones and is a leading cause of disability around the world.
Inflammatory arthritis may arise as the result of an autoimmune or autoinflammatory response. Examples include rheumatoid arthritis and spondyloarthropathies such as ankylosing spondylitis and psoriatic arthritis.
There is no known cure for arthritis, so current treatment strategies focus on providing effective palliation and slowing disease progression. Treatment may vary considerably depending upon type and severity.
To find out more about osteoarthritis, visit our dedicated Learning Zone, which contains further information on the treatment strategies, medications and relevant guidelines that are available to facilitate the successful management of this condition.
Related news and insights
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Remsima ((CT-P13 SC, biosimilar infliximab) from Celltrion Healthcare Hungary Kft.
Gilead Sciences, Inc. and Galapagos NV announced new analyses from two clinical trials evaluating filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with psoriatic arthritis (PsA).
AbbVie announced new Phase III data from the SELECT-CHOICE clinical trial in adult patients with moderate to severe active rheumatoid arthritis and prior inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (DMARDs), shows that Rinvoq (upadacitinib, 15 mg, once daily) met the primary endpoint of non-inferiority versus Orencia (abatacept) on change from baseline in Disease Activity Score 28 C-Reactive Protein (DAS28-CRP) at week 12. In addition, Rinvoq met the key secondary endpoints of superiority versus Orencia on change from baseline in DAS28-CRP at week 12 and proportion of patients achieving clinical remission at week 12 as measured by DAS28-CRP<2.6. the study evaluated rinvoq.
You may be interested in...
6th International Conference: Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment
The successful biannual ESH Conferences on acute myeloid leukemia (AML) have established themselves as scientific and educational programs at the interphase of molecular and biologic developments and clinical translation.
The Haematological Tumour Microenvironment and its Therapeutic Targeting 2021
This workshop brings together a constantly growing and international community of researchers, physicians and physician scientists, as well as biologists and physicians in training and corporate representatives, whose present or future work is focused on the tumor microenvironment in the haematological malignancies.